We are live on ! Find out more
KURA icon

Kura Oncology

200 hedge funds and large institutions have $743M invested in Kura Oncology in 2025 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 77 increasing their positions, 50 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

156% more call options, than puts

Call options by funds: $7.3M | Put options by funds: $2.85M

79% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 24

57% more capital invested

Capital invested by funds: $474M → $743M (+$269M)

54% more repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 50

10% more funds holding

Funds holding: 182200 (+18)

1.85% more ownership

Funds ownership: 94.8%96.65% (+1.9%)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

Holders
200
Holders Change
+18
Holders Change %
+9.89%
% of All Funds
2.62%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
43
Increased
77
Reduced
50
Closed
24
Calls
$7.3M
Puts
$2.85M
Net Calls
+$4.44M
Net Calls Change
+$4.27M

KURA Hedge Fund Activity: Q3 2025 in Review

200 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q3 2025, worth a combined $743M — up 57% from $474M a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new KURA positions and 24 closed out — a net gain of 19 holders — while 77 added to existing stakes and 50 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $12M. The largest seller was EcoR1 Capital, cutting an estimated $23.7M.

  • 200 institutional investors held Kura Oncology (KURA) as of Q3 2025, up from 182 in Q2 2025.
  • Funds reported $743M of Kura Oncology stock for Q3 2025, up 57% quarter-over-quarter.
  • 43 funds opened new Kura Oncology positions in Q3 2025 and 24 closed out, a net change of +19 holders.
  • The largest Kura Oncology buyer in Q3 2025 was Goldman Sachs, an estimated $12M added.
  • The largest Kura Oncology seller in Q3 2025 was EcoR1 Capital, an estimated $23.7M sold.

Based on aggregated 13F filings for Q3 2025.